• Augmentation of Sorafenib inhibitory effect by Mesenchymal Stem Cell Conditioned Media (MSC-CM) on Renal Cell Carcinoma Cells
  • Seyed Mohammad Reza Bolandi,1,* Arsalan Jalili,2 Amin Ebrahimi Sadrabadi,3
    1. Department of pharmacology, Faculty of veterinary medicine, Karaj Branch, Islamic Azad University, Karaj, Iran
    2. Hematopoietic Stem Cell Resesrch Center, Shahid Beheshti University of Madical Sciences, Tehran, Iran
    3. Cancer Biomedical Research Center, Tehran, Iran


  • Introduction: Sorafenib is a type of targeted cancer drug called a cancer growth blocker. It works in two ways. It stops signals that regulate cancer cells accumulate and block the angiogenesis process of cancer cells, so cancer development is prevented. Prescription of the High dosage of sorafenib cause many side effects and clinical complications, so much research has been done to reduce the toxicity and increase the inhibitory effect with low dosage. Mesenchymal stem cell (MSC) secretions express the anti-inflammatory, immune-modulating, anti-tumor, and regenerative characteristics which resulting from different stimuli or condition. In this project, we attempt to reduce the functional dose of sorafenib and increase its inhibitory effect parallelly.
  • Methods: One human RCC cell lines, Caki-1, has been treated with Sorafenib and MSC_CM separately and in co-administration. Then, the viability and proliferation effect of these treatments on cancer cells was evaluated by WST-8 at 96 hours.
  • Results: Compared to the mechanism of either agent alone, the combination of low concentrations of sorafenib (<5 μM) and MSC-CM, demonstrated the enhanced inhibition of cell proliferation and growth.
  • Conclusion: This study illustrated that co-administered of low dose sorafenib with MSC-CM synergistically augment its antitumor effect.
  • Keywords: RCC, Sorafenib, MSC-CM